Kazia Therapeutics Limited ADR (NASDAQ: KZIA) has experienced a decline in its stock price by -10.80 compared to its previous closing price of 6.39. However, the company has seen a fall of -10.94% in its stock price over the last five trading days. prnewswire.com reported 2024-11-04 that Company and FDA to meet in December to discuss potential pathways to registration of paxalisib in glioblastoma multiforme (GBM) Company updates to corporate presentation and participation in upcoming medical meetings SYDNEY, Nov. 4, 2024 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced that the U.S. Food and Drug Administration (FDA) has granted a Type C meeting with the Company in December 2024 to discuss the potential pathways to registration of Kazia’s blood brain barrier penetrant PI3K/mTOR inhibitor, paxalisib, for the treatment of patients with newly diagnosed GBM. In July 2024, the Company announced results from the Phase II/III clinical trial, GBM-AGILE, in which newly diagnosed unmethylated patients with glioblastoma treated with paxalisib showed clinically meaningful improvement in a prespecified secondary analysis for overall survival.
Is It Worth Investing in Kazia Therapeutics Limited ADR (NASDAQ: KZIA) Right Now?
The stock has a 36-month beta value of 2.04. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On November 14, 2024, the average trading volume of KZIA was 143.74K shares.
KZIA’s Market Performance
The stock of Kazia Therapeutics Limited ADR (KZIA) has seen a -10.94% decrease in the past week, with a 72.67% rise in the past month, and a 48.05% gain in the past quarter. The volatility ratio for the week is 12.80%, and the volatility levels for the past 30 days are at 16.17% for KZIA. The simple moving average for the past 20 days is -0.09% for KZIA’s stock, with a 59.21% simple moving average for the past 200 days.
Analysts’ Opinion of KZIA
Many brokerage firms have already submitted their reports for KZIA stocks, with Maxim Group repeating the rating for KZIA by listing it as a “Buy.” The predicted price for KZIA in the upcoming period, according to Maxim Group is $18 based on the research report published on October 14, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see KZIA reach a price target of $17. The rating they have provided for KZIA stocks is “Buy” according to the report published on January 05th, 2021.
KZIA Trading at 25.71% from the 50-Day Moving Average
After a stumble in the market that brought KZIA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.92% of loss for the given period.
Volatility was left at 16.17%, however, over the last 30 days, the volatility rate increased by 12.80%, as shares surge +70.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +49.18% upper at present.
During the last 5 trading sessions, KZIA fell by -10.94%, which changed the moving average for the period of 200-days by +91.66% in comparison to the 20-day moving average, which settled at $5.70. In addition, Kazia Therapeutics Limited ADR saw 29.69% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for KZIA
Current profitability levels for the company are sitting at:
- -34631.15 for the present operating margin
- 1.0 for the gross margin
The net margin for Kazia Therapeutics Limited ADR stands at -28040.47. The total capital return value is set at -1.49. Equity return is now at value -181.74, with -58.59 for asset returns.
Based on Kazia Therapeutics Limited ADR (KZIA), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -35.3.
Currently, EBITDA for the company is -22.28 million with net debt to EBITDA at 0.18. When we switch over and look at the enterprise to sales, we see a ratio of 38554.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.71.
Conclusion
To sum up, Kazia Therapeutics Limited ADR (KZIA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
